Literature DB >> 12062387

Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.

Guy Boivin1, Nathalie Goyette.   

Abstract

Forty-two influenza A and 23 influenza B isolates collected from untreated subjects during the 1999-2000 influenza season in Canada were tested for their susceptibility to three neuraminidase inhibitors (zanamivir, oseltamivir carboxylate and RWJ-270201 or BCX-1812) using a chemiluminescent neuraminidase assay. Influenza B isolates were less susceptible than A viruses to all tested drugs. RWJ-270201 was the most potent drug against both influenza A(H3N2) (mean IC(50): 0.60 nM) and B (mean IC(50): 0.87 nM) viruses. Oseltamivir carboxylate was more active than zanamivir for influenza A(H3N2) isolates (mean IC(50): 0.73 vs. 2.09 nM) whereas it was less potent against B viruses (mean IC(50): 11.53 vs. 4.15 nM).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12062387     DOI: 10.1016/s0166-3542(01)00219-4

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  16 in total

1.  Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.

Authors:  Yacine Abed; Andrés Pizzorno; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Prediction of zanamivir efficiency over the possible 2009 influenza A (H1N1) mutants by multiple molecular dynamics simulations and free energy calculations.

Authors:  Dabo Pan; Huijun Sun; Chongliang Bai; Yulin Shen; Nengzhi Jin; Huanxiang Liu; Xiaojun Yao
Journal:  J Mol Model       Date:  2010-12-31       Impact factor: 1.810

3.  Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase.

Authors:  Ye Wang; Di Wu; Dahai Yu; Zhiyong Wang; Li Tian; Yanyan Wang; Weiwei Han; Xuexun Fang
Journal:  J Mol Model       Date:  2012-01-27       Impact factor: 1.810

Review 4.  The threat of avian influenza A (H5N1). Part III: Antiviral therapy.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-04-12       Impact factor: 3.402

5.  Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer.

Authors:  Silvana Carr; Natalia A Ilyushina; John Franks; Elisabeth E Adderson; Miguela Caniza; Elena A Govorkova; Robert G Webster
Journal:  Pediatr Infect Dis J       Date:  2011-04       Impact factor: 2.129

6.  Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques.

Authors:  Mitsutaka Kitano; Yasushi Itoh; Makoto Kodama; Hirohito Ishigaki; Misako Nakayama; Hideaki Ishida; Kaoru Baba; Takahiro Noda; Kenji Sato; Yoichiro Nihashi; Takushi Kanazu; Ryu Yoshida; Ryuzo Torii; Akihiko Sato; Kazumasa Ogasawara
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

7.  Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.

Authors:  Yacine Abed; Philippe Simon; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

8.  Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.

Authors:  James J McSharry; Ann C McDonough; Betty A Olson; George L Drusano
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

9.  Economic evaluations of neuraminidase inhibitors to control influenza.

Authors:  Michaël Schwarzinger; Karine Lacombe; Fabrice Carrat
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2003-04       Impact factor: 2.217

10.  Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy.

Authors:  Morgan Lawrenz; Jeff Wereszczynski; Rommie Amaro; Ross Walker; Adrian Roitberg; J Andrew McCammon
Journal:  Proteins       Date:  2010-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.